STIM Neuronetics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Neuronetics, Inc. (STIM) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 17, 2026, a 10-Q quarterly report filed on November 4, 2025, an 8-K current report filed on April 6, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Neuronetics, Inc. (STIM) (SEC CIK 1227636), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: Development and commercialization of NeuroStar Advanced Therapy System, a non-invasive TMS treatment for MDD and OCD, plus operation of Greenbrook mental health treatment centers
- • New emphasis on fully integrated care via Greenbrook acquisition, adding 93 clinics and SPRAVATO treatment for treatment-resistant depression
Risk Factors
- • Cybersecurity risk oversight by board Audit Committee with quarterly enterprise risk profile reports from Head of IT
- • Head of IT with 20+ years experience leads cybersecurity program and partners with third-party experts for risk identification
Management Discussion & Analysis
- • Revenue $149.2M in 2025, up 99% YoY from $74.9M in 2024; U.S. revenue $146.0M up 101% YoY; international $3.1M up 29% YoY
- • Gross margin 48.5% in 2025 vs 72.3% in 2024, decline due to Greenbrook clinic business inclusion and reduced treatment session revenue
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • New CEO Daniel Reuvers starts March 23, 2026; age 63 with 35+ years medtech experience including CEO of Tactile Medical (TCMD) 2020–2024
- • Base salary $730,000 with target annual bonus at 100% of base salary (~$730,000 target total cash)
Item 7.01: Regulation FD Disclosure
- • Forward-looking statements cover revenue, expenses, growth outlook for upcoming quarters and full-year fiscal 2026
- • Key risk flags: reliance on NeuroStar system for all revenue, history of losses, ability to maintain positive cash flow
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 earnings released March 17, 2026 — covering period ended December 31, 2025
- • Full financial details in Exhibit 99.1 press release; key figures not disclosed in this filing item
Item 1.01: Entry into a Material Definitive Agreement
- • Madryn Parties (major shareholder from Greenbrook TMS merger) granted registration rights to resell STIM shares received as deal consideration
- • Key new term: if Shelf Notice received, Neuronetics must file resale registration statement within 5 business days after filing its 2025 10-K — creates near-term share overhang risk
Annual Reports Archive10-K
AI-powered analysis of Neuronetics, Inc. (STIM) 10-K annual reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Neuronetics, Inc. (STIM) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | — | $71.3M | $74.9M | $149.2M |
| Gross Profit | $49.7M | $51.7M | $54.2M | $72.3M |
| Operating Income | — | -$30.6M | -$34.6M | -$31.4M |
| Net Income | — | -$30.2M | -$43.7M | -$39.0M |
| Gross Margin | — | 72.5% | 72.3% | 48.5% |
| Op. Margin | — | -42.8% | -46.2% | -21.1% |
| Net Margin | — | -42.3% | -58.4% | -26.1% |
| Balance Sheet | ||||
| Total Assets | — | $115.8M | $140.9M | $141.6M |
| Equity | $57.1M | $34.2M | $27.7M | $22.4M |
| ROE | — | -88.3% | -157.8% | -174.3% |
Source: XBRL financial data from Neuronetics, Inc. (STIM) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 6, 2026 | — | — | — |
8-K | Mar 17, 2026 | — | Analysis | — |
10-K | Mar 17, 2026 | Dec 31, 2025 | Analysis | |
8-K | Mar 2, 2026 | — | Analysis | — |
8-K | Feb 25, 2026 | — | Analysis | — |
8-K | Feb 10, 2026 | — | — | |
8-K | Jan 22, 2026 | — | — | |
8-K | Jan 6, 2026 | — | — | |
10-Q | Nov 4, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 5, 2025 | Jun 30, 2025 | — | |
10-Q | May 6, 2025 | Mar 31, 2025 | — | |
10-K | Mar 27, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 12, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 12, 2024 | Jun 30, 2024 | — | |
10-Q | May 7, 2024 | Mar 31, 2024 | — | |
10-K | Mar 8, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 7, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 8, 2023 | Jun 30, 2023 | — | |
10-Q | May 15, 2023 | Mar 31, 2023 | — | |
10-K | Mar 7, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 8, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 2, 2022 | Jun 30, 2022 | — | |
10-Q | May 12, 2022 | Mar 31, 2022 | — | |
10-K | Mar 8, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 9, 2021 | Sep 30, 2021 | — |
Frequently Asked Questions
What are the latest STIM SEC filings in 2026?
Neuronetics, Inc. (STIM) has filed a 10-K annual report on March 17, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on April 6, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did STIM file its most recent 10-K annual report?
Neuronetics, Inc. (STIM) filed its most recent 10-K annual report on March 17, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view STIM 10-Q quarterly reports?
Neuronetics, Inc. (STIM)'s most recent 10-Q quarterly report was filed on November 4, 2025. SignalX displays every STIM 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has STIM filed recently?
Neuronetics, Inc. (STIM)'s most recent 8-K was filed on April 6, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find STIM insider trading activity (Form 4)?
SignalX aggregates every STIM Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does STIM file with the SEC?
Neuronetics, Inc. (STIM) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new STIM filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Neuronetics, Inc. (STIM).
What is STIM's SEC CIK number?
Neuronetics, Inc. (STIM)'s SEC CIK (Central Index Key) number is 1227636. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1227636 to look up all STIM filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find STIM return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Neuronetics, Inc. (STIM) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Neuronetics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 38+ filings.